Anteris Technologies Global Corp. — Capital/Financing Update 2023

Oct 12, 2023

==> picture [192 x 28] intentionally omitted <==

ASX ANNOUNCEMENT

13 October 2023

Anteris Receives $1.4m R&D Tax Refund

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) recently received $1.4M under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme. The claim covers the year ended 31 December 2022.

The Company will use the refund in the R&D of its ADAPT[®] , DurAVR[TM] and ComASUR[TM ] technologies.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR[TM] , is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR[TM] THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[TM] THV is made using ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR[TM] Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR[TM] THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

==> picture [41 x 40] intentionally omitted <==

REGISTERED OFFICE Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD 4066 Australia

T: +61 1300 550 310 info.au@anteristech.com anteristech.com

BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

==> picture [195 x 28] intentionally omitted <==

For more information:

Investor Relations (US)

Malini Chatterjee, Ph.D. Managing Director Blueprint Life Science Group +1 917 330 4269

Investor Relations

investors@anteristech.com Anteris Technologies Ltd +61 1300 550 310 | +61 7 3152 3200

Website www.anteristech.com Twitter @AnterisTech Facebook www.facebook.com/AnterisTech LinkedIn https://www.linkedin.com/company/anteristech

==> picture [41 x 40] intentionally omitted <==